Werewolf Therapeutics Analyst Ratings
Werewolf Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 584.93% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 10/31/2023 | 584.93% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 09/19/2023 | 584.93% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 09/15/2023 | 584.93% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 08/24/2023 | 310.96% | Wedbush | → $9 | Initiates Coverage On | → Outperform |
| 08/10/2023 | 584.93% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/25/2023 | 279% | EF Hutton | → $8.3 | Assumes | → Buy |
| 05/12/2023 | 356.62% | B of A Securities | $9 → $10 | Maintains | Buy |
| 05/11/2023 | 584.93% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 03/24/2023 | 279% | EF Hutton | → $8.3 | Reiterates | → Buy |
| 03/23/2023 | 310.96% | B of A Securities | → $9 | Reiterates | Buy → Buy |
| 03/23/2023 | 584.93% | HC Wainwright & Co. | $20 → $15 | Reiterates | → Buy |
| 02/27/2023 | 279% | EF Hutton | → $8.3 | Reiterates | → Buy |
| 02/17/2023 | 279% | EF Hutton | → $8.3 | Reiterates | → Buy |
| 01/30/2023 | 265.3% | B of A Securities | $9 → $8 | Maintains | Buy |
| 12/05/2022 | 279% | EF Hutton | → $8.3 | Initiates Coverage On | → Buy |
| 06/02/2022 | 813.24% | HC Wainwright & Co. | → $20 | Assumes | → Buy |
| 05/11/2022 | 676.26% | SVB Leerink | $18 → $17 | Maintains | Outperform |
| 11/19/2021 | 1178.54% | SVB Leerink | $29 → $28 | Maintains | Outperform |
| 09/10/2021 | 1087.21% | B of A Securities | → $26 | Initiates Coverage On | → Buy |
| 05/25/2021 | 950.23% | Evercore ISI Group | → $23 | Initiates Coverage On | → Outperform |
| 05/25/2021 | 1224.2% | SVB Leerink | → $29 | Initiates Coverage On | → Outperform |
| 05/25/2021 | 904.57% | Jefferies | → $22 | Initiates Coverage On | → Buy |
| 05/25/2021 | 1361.19% | HC Wainwright & Co. | → $32 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/15/2023 | 584.93% | HC Wainwright & Co. | → 15 美元 | 重申 | 購買 → 購買 |
| 10/31/2023 | 584.93% | HC Wainwright & Co. | → 15 美元 | 重申 | 購買 → 購買 |
| 09/19/2023 | 584.93% | HC Wainwright & Co. | → 15 美元 | 重申 | 購買 → 購買 |
| 09/15/2023 | 584.93% | HC Wainwright & Co. | → 15 美元 | 重申 | 購買 → 購買 |
| 08/24/2023 | 310.96% | Wedbush | → 9 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 08/10/2023 | 584.93% | HC Wainwright & Co. | → 15 美元 | 重申 | 購買 → 購買 |
| 05/25/2023 | 279% | EF Hutton | → 8.3 美元 | 假設 | → 購買 |
| 05/12/2023 | 356.62% | B of A 類證券 | 9 美元 → 10 美元 | 維護 | 買 |
| 05/11/2023 | 584.93% | HC Wainwright & Co. | → 15 美元 | 重申 | 購買 → 購買 |
| 2023 年 3 月 24 日 | 279% | EF Hutton | → 8.3 美元 | 重申 | → 購買 |
| 03/23/2023 | 310.96% | B of A 類證券 | → 9 美元 | 重申 | 購買 → 購買 |
| 03/23/2023 | 584.93% | HC Wainwright & Co. | 20 美元 → 15 美元 | 重申 | → 購買 |
| 02/27/2023 | 279% | EF Hutton | → 8.3 美元 | 重申 | → 購買 |
| 02/17/2023 | 279% | EF Hutton | → 8.3 美元 | 重申 | → 購買 |
| 01/30/2023 | 265.3% | B of A 類證券 | 9 美元 → 8 美元 | 維護 | 買 |
| 12/05/2022 | 279% | EF Hutton | → 8.3 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 06/02/2022 | 813.24% | HC Wainwright & Co. | → 20 美元 | 假設 | → 購買 |
| 05/11/2022 | 676.26% | SVB Leerink | 18 美元 → 17 美元 | 維護 | 跑贏大盤 |
| 11/19/2021 | 1178.54% | SVB Leerink | 29 美元 → 28 美元 | 維護 | 跑贏大盤 |
| 2021 年 10 月 9 日 | 1087.21% | B of A 類證券 | → 26 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 5 月 25 日 | 950.23% | Evercore ISI 集團 | → 23 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 5 月 25 日 | 1224.2% | SVB Leerink | → 29 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 5 月 25 日 | 904.57% | 傑富瑞集團 | → 22 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 5 月 25 日 | 1361.19% | HC Wainwright & Co. | → 32 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Werewolf Therapeutics (HOWL)?
Werewolf Therapeutics（HOWL）的目標價格是多少？
The latest price target for Werewolf Therapeutics (NASDAQ: HOWL) was reported by HC Wainwright & Co. on November 15, 2023. The analyst firm set a price target for $15.00 expecting HOWL to rise to within 12 months (a possible 584.93% upside). 16 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月15日公佈了Werewolf Therapeutics（納斯達克股票代碼：HOWL）的最新目標股價。該分析公司將目標股價定爲15.00美元，預計HOWL將在12個月內升至12個月內（可能上漲584.93％）。去年有16家分析公司公佈了評級。
What is the most recent analyst rating for Werewolf Therapeutics (HOWL)?
Werewolf Therapeutics（HOWL）的最新分析師評級是多少？
The latest analyst rating for Werewolf Therapeutics (NASDAQ: HOWL) was provided by HC Wainwright & Co., and Werewolf Therapeutics reiterated their buy rating.
Werewolf Therapeutics（納斯達克股票代碼：HOWL）的最新分析師評級由HC Wainwright & Co. 提供，Werewolf Therapeutics重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Werewolf Therapeutics (HOWL)?
Werewolf Therapeutics（HOWL）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Werewolf Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Werewolf Therapeutics was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Werewolf Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Werewolf Therapeutics的最新評級是在2023年11月15日發佈的，因此您應該預計下一個評級將在2024年11月15日左右公佈。
Is the Analyst Rating Werewolf Therapeutics (HOWL) correct?
分析師對 Werewolf Therapeutics（HOWL）的評級正確嗎？
While ratings are subjective and will change, the latest Werewolf Therapeutics (HOWL) rating was a reiterated with a price target of $0.00 to $15.00. The current price Werewolf Therapeutics (HOWL) is trading at is $2.19, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的Werewolf Therapeutics（HOWL）評級，目標股價爲0.00美元至15.00美元。Werewolf Therapeutics（HOWL）目前的交易價格爲2.19美元，在分析師的預期區間內。
譯文內容由第三人軟體翻譯。